“AI” in Bioprocessing – What’s Behind the Buzzword?

At the 2026 Global Bioprocessing & Biotechnology Summit in Berlin, “AI” was a hot topic – from media development and enzyme screening to manufacturing, clinical data analysis and supply chain optimization. “AI” in current and cutting edge bioprocessing is rarely about artificial intelligence in the popular sense, meaning large language models (LLMs). Instead, many developments build on, and integrate machine learning into, a well-established toolkit of modelling, simulation, and automation.

What "AI" in Bioprocessing Means Today

Across multiple talks, a consistent pattern emerged:

• Statistical modelling and DoE remain central to process development. For example, media optimisation relies heavily on design of experiments (DoE), multivariate data analysis (MVDA), and metabolic profiling to identify critical components and optimal parameter spaces.
• High-throughput, automated experimentation – often framed as “AI-enabled” – combines robotics with algorithmic DoE and iterative optimisation loops to explore process space efficiently.
• Simulation and digital twins are increasingly used in supply chain and manufacturing planning to evaluate scenarios and improve decision-making speed and robustness.
• Process Analytical Technology (PAT) provides real-time, high-frequency process data (e.g. every few seconds instead of daily offline measurements), enabling continuous monitoring and control.

These approaches are powerful – but importantly, they are not new. They represent the continued evolution and integration of modelling, statistics, and automation rather than a fundamentally new “AI revolution.”

In fact, several speakers implicitly confirmed this: what is often labelled as “AI-driven” is, in practice, the systematic combination of data, models, and automated workflows.

Where the Gap Still Exists and Where LLMs Can Add Value

Despite the sophistication of these existing tools, a few key bottleneck remains:

• Bioprocessing generates large, complex datasets
• Analysis workflows are often slow, manual, and difficult to reproduce
• Specialist expertise is required, limiting accessibility and scalability

This “data-to-insight gap” was exemplified in relation to bioinformatics and clinical data, where analyses can take weeks to months and delay downstream decisions. And this is where LLMs can potentially contribute.

Rather than replacing existing models with black-box machine learning, some proposed approaches use AI as a smart interface layer, namely LLMs as a chat-based orchestrator. Users interact with LLMs in a chat window to instruct the processing of data and interrogate results that the AI can fetch by the AI system having access to models and analytical tools.

Crucially, such AI systems do not “look at” or train on sensitive data themselves – they simply connect datasets with existing analytical pipelines that are running validated, published methods by using the metadata included with the dataset. The user can ask for specific information via natural language, and the AI delivers the desired analysis. This addresses both usability and data security concerns. Workflows that previously took weeks can be executed in hours, or by users without deep knowledge of the analytical tools, without risking the exposure of proprietary data to third parties.

This example illustrates where LLMs may genuinely add value: not by replacing established modelling approaches or running analyses (which other types of computational analyses tools, some of which include machine learning components, are better suited for), but by making those established modelling tools accessible, integrated, and efficient.

Take-Home Message and Outlook

The key message seems simple: At the moment, progress in bioprocessing is driven more by digitalisation than by AI in the narrow sense. The main value lies in integrating modelling, automation, and real-time data into efficient, accessible workflows to support decisions earlier and faster and improve how experts interact with data and models.

In the near term, the greatest gains will probably continue to come from combining established modelling approaches with automation and improved data access. In this sense, AI in bioprocessing is not a disruptive break – it can be an evolution towards smarter, more user-friendly digital systems.